Señales en vivo de MNPR | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (20 may 2024 @ 16:00):

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States...

Stats
Volumen de hoy	57 703.00
Volumen promedio	3.89M
Capitalización de mercado	10.84M
EPS	$0 ( 2024-05-09 )
Próxima fecha de ganancias	( $-0.0900 ) 2024-08-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.190
ATR14	$0.00400 (0.65%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-31	Cittadine Andrew	Sell	8 952	Restricted Stock Units
2024-03-31	Cittadine Andrew	Buy	8 952	Common Stock
2024-03-31	Cittadine Andrew	Sell	3 098	Common Stock
2024-03-31	Tsuchimoto Kim R	Sell	9 956	Restricted Stock Units
2024-03-31	Tsuchimoto Kim R	Buy	9 956	Common Stock

INSIDER POWER
36.22
Last 100 transactions
Buy: 1 127 208 \| Sell: 341 037

Volumen Correlación

Largo: -0.17 (neutral)

Corto: -0.88 (strong negative)

Signal:(57.23) Neutral

Monopar Therapeutics Inc Correlación

10 Correlaciones Más Positivas
LRMR	0.885
COGT	0.853
CFLT	0.823

10 Correlaciones Más Negativas
BLKB	-0.804

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Monopar Therapeutics Inc Correlación - Moneda/Commodity

0.23
( neutral )

0.24
( neutral )

0.00
( neutral )

-0.16
( neutral )

Monopar Therapeutics Inc Finanzas

Annual	2023
Ingresos:	$0
Beneficio Bruto:	$0 (0.00 %)
EPS:	$-0.610

FY	2023
Ingresos:	$0
Beneficio Bruto:	$0 (0.00 %)
EPS:	$-0.610

FY	2022
Ingresos:	$0
Beneficio Bruto:	$0 (0.00 %)
EPS:	$-0.830

FY	2021
Ingresos:	$0.00
Beneficio Bruto:	$0.00 (0.00 %)
EPS:	$-0.730

Financial Reports:

No articles found.

Monopar Therapeutics Inc Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Monopar Therapeutics Inc

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to potentially treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was incorporated in 2014 and is headquartered in Wilmette, Illinois.